Medicare Proposal on Alzheimer’s Drug Draws Criticism From Drugmakers
Drugmakers and patient advocacy groups are pushing back against a federal proposal to cut off most Medicare payments for Biogen Inc.’s new Alzheimer’s drug, contending the healthcare agency is overstepping the bounds of its…